Ladostigil, TV-3,326

(N-propargyl-(3R) aminoindan-5yl)-ethyl methyl carbamate

(3R)-3-(Prop-2-ynylamino)indan-5-yl ethyl(methyl)carbamate; R-CPAI

Carbamic acid, ethylmethyl-, (3R)-2,3-dihydro-3-(2-propynylamino)-1H-inden-5-yl ester

Condition(s): Mild Cognitive Impairment
U.S. FDA Status: Mild Cognitive Impairment (Phase 2)
Company: Avraham Pharmaceuticals Ltd

Target Type: Cholinergic System

CAS No:	209349-27-4
Synonyms:	Ladostigil, TV-3326, UNII-SW3H1USR4Q
Molecular Weight:	272.346 g/mol

Chemical Formula:	C16-H20-N2-O2

IUPAC Name:	(3R)-3-(Prop-2-ynylamino)indan-5-yl ethyl(methyl)carbamate N-Propargyl-(3R)-aminoindan-5-yl) ethyl methyl carbamate

Ladostigil tartrate Structure

CAS 209394-46-7, Ladostigil tartrate

N-Ethyl-N-methylcarbamic acid 3(R)-(2-propynylamino)-2,3-dihydro-1H-inden-5-yl ester L-tartrate

In 2010, ladostigil tartrate was licensed by Technion Research & Development Foundation and Yissum to Avraham for the treatment of Alzheimer’s disease and other neurogenerative diseases.

Ladostigil (TV-3,326) is a novel neuroprotective agent being investigated for the treatment of neurodegenerative disorders likeAlzheimer’s disease, Lewy body disease, and Parkinson’s disease.^[1] It acts as a reversible acetylcholinesterase andbutyrylcholinesterase inhibitor, and an irreversible monoamine oxidase B inhibitor, and combines the mechanisms of action of older drugs like rivastigmine and rasagiline into a single molecule.^[2]^[3] In addition to its neuroprotective properties, ladostigil enhances the expression of neurotrophic factors like GDNF and BDNF, and may be capable of reversing some of the damage seen in neurodegenerative diseases via the induction of neurogenesis.^[4] Ladostigil also has antidepressant effects, and may be useful for treating comorbid depression and anxiety often seen in such diseases as well.^[5]^[6]

Ladostigil [(N-propargyl-(3R) aminoindan-5yl)-ethyl methyl carbamate] is a dual acetylcholine-butyrylcholineesterase and brain selective monoamine oxidase (MAO)-A and -B inhibitor in vivo (with little or no MAO inhibitory effect in the liver and small intestine), intended for the treatment of dementia co-morbid with extrapyramidal disorders and depression (presently in a Phase IIb clinical study). This suggests that the drug should not cause a significant potentiation of the cardiovascular response to tyramine, thereby making it a potentially safer antidepressant than other irreversible MAO-A inhibitors. Ladostigil was shown to antagonize scopolamine-induced impairment in spatial memory, indicating that it can cause significant increases in rat brain cholinergic activity. Furthermore, ladostigil prevented gliosis and oxidative-nitrative stress and reduced the deficits in episodic and spatial memory induced by intracerebroventricular injection of streptozotocin in rats. Ladostigil was demonstrated to possess potent anti-apoptotic and neuroprotective activities in vitro and in various neurodegenerative rat models, (e.g. hippocampal damage induced by global ischemia in gerbils and cerebral oedema induced in mice by closed head injury). These neuroprotective activities involve regulation of amyloid precursor protein processing; activation of protein kinase C and mitogen-activated protein kinase signaling pathways; inhibition of neuronal death markers; prevention of the fall in mitochondrial membrane potential and upregulation of neurotrophic factors and antioxidative activity. Recent findings demonstrated that the major metabolite of ladostigil, hydroxy-1-(R)-aminoindan has also a neuroprotective activity and thus, may contribute to the overt activity of its parent compound. This review will discuss the scientific evidence for the therapeutic potential use of ladostigil in Alzheimer’s and Lewy Body diseases and the molecular signaling pathways that are considered to be involved in the biological activities of the drug

LADOSTIGIL

Recently, Yissum Research Development Company associated with the Hebrew University of Jerusalem announced that the University will use a portion of a $9 million dollar grant awarded to Avraham Pharmaceuticals, Pontifax, Clal Biotechnology Industries and Professor Marta Weinstock-Rosin to complete the Phase II efficacy trial in patients afflicted with Alzheimer’s disease.

The trial will be conducted over the course of 52 weeks and will involve the novel drug, Ladostigil. Ladostigil is a new comprehensive drug used to combat symptoms of Alzheimer’s, Parkinson’s, depression, and anxiety. The drug is deemed multi-functional because it addresses a host of neurodegenerative problems. Ladostigil is a brain-selective monoamine oxidase inhibitor (MAOI) that protects the neurons.

PATENT

US 20140243544 http://www.google.co.in/patents/US20140243544

PATENT

WO 2008074816

http://www.google.com/patents/WO2008074816A1?cl=en

Ethylmethyl carbamyl chloride (15.5 g, 127.57 mmol) was added to a stirred suspension of 6-hydroxy-1-indanone (17.2 g, 116.1 mmol) and potassium carbonate (31.8 g, 188 mmol) in acetonitrile (800 mL) at room temperature over a period of 15 minutes. The reaction mixture was heated to reflux and refluxed for 18 hours. The reaction mixture was cooled to ambient temperature, the solvent evaporated and the residue was diluted with water (250 mL) and extracted three times with toluene (250 mL). The combined organic phase was dried on MgSO and toluene was evaporated in a rotary evaporator. The crude crystalline product was purified by crystallization from 2-propanol (200 mL), collected by filtration, and dried under vacuum at 50° C. to afford the title compound (22 g, 81.5%).

1H NMR (300 MHz, CDCl₃) δ ppm 7.47-7.44 (2H, m, Ar), 7.36 (1H, dd, J 8.4 and 2.1, Ar), 3.52-3.37 (2H, m, NCH₂CH₃), 3.14-3.108 [2H, m, OCCH₂CH₂and incl. NCH₃(two rotamers), at 3.08 and 2.99 (3H, s, Me)], 2.74-2.71 (2H, m, OCCH₂CH₂) and 1.25 and 1.19 (two rotamers) (3H,two triplets, J 6.9). Mass Spectrum (FAB+) [MH⁺=234

Example 6(S)-Dimethyl-carbamic acid 3-prop-2-ynylamino-indan-5-yl ester

Methanesulfonyl anhydride (296 mg, 1.7 mmol) as a solution in dichloromethane (1.5 mL+0.5 mL) was added to a stirred solution of (R)-dimethyl-methyl-carbamic acid 3-hydroxy-indan-5-yl ester (188 mg, 0.8 mmol, product of example 1a) and triethylamine (0.47 mL, 3.4 mmol) in dichloromethane (2 mL) at −78° C. (external) over 10 minutes. The reaction was maintained at this temperature for 1 hour before propargylamine (1.20 mL, 17.0 mmol) was added. The reaction was allowed to warm slowly to room temperature overnight before being partitioned between ethyl acetate (20 mL) and ice-water (20 mL). The organic material was concentrated under reduced pressure to afford a brown oil which was partitioned between methyl tert-butyl ether (10 mL) and aqueous hydrochloric acid (1M, 10 mL). The aqueous layer was basified by addition of aqueous sodium hydroxide solution (2M, 16 mL) before being extracted with ethyl acetate (10 mL). This final organic extract was dried (MgSO₄), filtered and concentrated under reduced pressure to afford the title compound (175 mg, 80%). ¹H NMR (400 MHz, CDCl₃) δ ppm 7.19 (1H, d, J 8, Ar), 7.09 (1H, d, J 2, Ar), 6.94 (1H, dd, J 8 and 2, Ar), 4.39 (1H, dd, J 6 and 6, CHNH), 3.54 (1H, Dd, J 17 and 3, NCHH), 3.49 (1H, Dd, J 16 and 3, HNCHH), 3.09 (3H, s, Me), 3.03-2.96 [4H, m, NCHCHH and Me incl. at 3.00 (3H, s, Me)], 2.83-2.75 (1H, m, NCHCHH), 2.48-2.39 (1H, m, NCHCH₂CHH), 2.25 (1H, t, J 2, ≡CH) and 1.92-1.83 (1H, m, NCHCH₂CHH). Analysis of this material by chiral LC indicated it to be 70% e.e.

Example 7b(R)-Ethyl-methyl-carbamic acid 3-prop-2-ynylamino-indan-5-yl ester (ladostigil)

The procedure of example 7a is repeated with (S)-ethyl-methyl-carbamic acid 3-hydroxy-indan-5-yl ester instead of (R)-ethyl-methyl-carbamic acid 3-hydroxy-indan-5-yl ester. The R-enantiomer is produced.

PAPER

Tetrahedron: Asymmetry (2012), 23(5), 333-338

http://www.sciencedirect.com/science/article/pii/S0957416612001334

Image for unlabelled figure

(R)-3-(Prop-2-ynylamino)-2,3-dihydro-1H-inden-5-yl ethyl(methyl)carbamate

C₁₆H₂₀N₂O₂

ee: 89%

(c 1.46, CHCl₃)

Source of chirality: the precursor

Absolute configuration: (R)

(R)-3-(Prop-2-ynylamino)-2,3-dihydro-1H-inden-5-yl ethyl(methyl)carbamate hemi((2R,3R)-2,3-dihydroxysuccinate)

C₃₆H₄₆N₄O₁₀

ee: 99%

(c1.95, CHCl₃)

Source of chirality: the precursor

Absolute configuration: (R,R,R)

Avraham Pharmaceuticals Announces Commencement of a Phase 2 Study of Ladostigil for the Treatment of MCI

Posted on May 17, 2012

Yaacov Michlin appointed Chairman of the Board and Dr. Yona Geffen appointed Chief Executive Officer

Yavne, Israel, May 17, 2012 — Avraham Pharmaceuticals Ltd. announced today the commencement of a Phase 2 clinical trial to evaluate the safety and efficacy of ladostigil in patients diagnosed with mild cognitive impairment (MCI). This 36-month, multi-centre, randomized, double-blind, placebo-controlled trial will include at least 200 patients in 16 centers in Europe and Israel.

In parallel, Avraham Pharmaceuticals has also completed the enrollment of 200 patients in a Phase 2 trial of ladostigil, a novel molecule for the treatment of mild to moderate Alzheimer’s disease. The Phase 2 study is a double-blind, closed-label, placebo-controlled trial taking place at 20 sites in five countries across Europe. In January 2012, the Company performed an interim analysis of this Phase 2 trial, which indicated that the drug is safe and well tolerated, as well as shows a positive trend toward efficacy. Final results of the 26-week trial are expected in the fourth quarter of 2012.

The Company also announced today that it has appointed Yaacov Michlin, CEO of Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., the technology transfer arm of the University, as Chairman of the Board and Yona Geffen, Ph.D., as Chief Executive Officer.

“We strongly believe in ladostigil and are confident that Yona’s background and extensive experience in developing therapies for neurological disorders and neurodegenerative diseases renders her the perfect choice to lead Avraham,” said Yaacov Michlin, Chairman of Avraham Pharmaceuticals and Chief Executive Officer of Yissum. “In further researches performed by Prof. Weinstock-Rosin, ladostigil has showed promise also for the treatment of MCI in addition to Alzheimer’s disease. We are pleased that another Phase 2 clinical trial in patients with MCI has begun in parallel, and look forward to the final results of the Phase 2 study for the treatment of Alzheimer’s disease expected at the end of this year.”

“I am delighted to lead Avraham in these exciting times for the company, as we advance ladostigil in 2 Phase 2 clinical trials simultaneously. We believe that this unique drug candidate has the potential to transform the treatment of various neurodegenerative diseases,” said Dr. Yona Geffen, Avraham Pharmaceuticals Chief Executive Officer.

Dr. Yona Geffen joined Avraham Pharmaceuticals in January 2011 as Senior Vice President of Clinical Affairs and Chief Operating Officer. Dr. Geffen has more than 12 years of experience in the field of drug development in biopharmaceutical companies. Prior to Avraham, she was Executive Drug Development Director at BiolineRx (NASDAQ: BLRX). Before that, Dr. Geffen was a project manager at Proneuron Biotechnologies. Dr. Geffen received her Ph.D. from Ben Gurion University in Beer Sheva, Israel. She also holds an M.Sc. in business management.

Yaacov Michlin has been CEO of Yissum since 2009. Prior to Yissum, Mr. Michlin spent over a decade in leading and assisting pharmaceutical, hi-tech and biomedical companies in various technology commercialization deals, licensing agreements, capital raising activities, partnerships, mergers and acquisitions. Michlin holds a Bachelor of Law and Economics cum laude, and a Master of Law all from Bar-Ilan University, Ramat Gan, Israel. In addition, he has an MBA cum laude from the Technion Israel Institute of Technology, Haifa, Israel.

About Ladostigil

Ladostigil is a novel cholinesterase and brain-selective monoamine oxidase inhibitor, and neuroprotective agent for the treatment of Alzheimer’s disease, mild cognitive impairment and other neurodegenerative diseases. The drug, which was exclusively licensed to Avraham Pharmaceuticals by Yissum Research Development Company Ltd., and by the Technion Research and Development Foundation Ltd. (TRDF), has proven to be safe and well tolerated in Phase 1 and Phase 2 clinical trials. Like other cholinesterase inhibitors currently on the market, ladostigil targets symptomatic relief in Alzheimer’s disease patients. But unlike these drugs, ladostigil, which also causes brain selective inhibition of monoamine oxidase (MAO) provides the potential to improve the behavioral and psychological symptoms of dementia such as depression and anxiety. Moreover, ladostigil has the potential to slow progression of clinical symptoms of Alzheimer’s disease for sustained periods of time and to modify the pathology associated with the disease. In addition, the neuroprotective activity of ladostigil provides a drug candidate that may have the potential to slow progression to Alzheimer’s disease in patients diagnosed with MCI. This potential has been amply demonstrated in animal models, especially in studies of ageing rats.

Ladostigil was designed by Professor Marta Weinstock-Rosin of the Hebrew University of Jerusalem, inventor of Exelon® and Professor Moussa B.H. Youdim of the Technion Israel Institute of Technology, inventor of Azilect®. The drug substance was first synthesized by Professor Michael Chorev of the Hebrew University, who is now based at Harvard University. All three distinguished scientists act as scientific advisors to Avraham Pharmaceuticals.

About Alzheimer’s Disease

Alzheimer’s disease is the most common cause of dementia worldwide, affecting about one in 20 people 65 years of age or older, accounting for 60-80% of dementia cases. In 2010, 5.4 million people were affected by Alzheimer’s disease in the U.S., where it is the 6th leading cause of death. In Europe, more than 6 million are living with the disease. Approximately half of Alzheimer’s patients also suffer from depression, and up to 40% also exhibit Parkinson-like symptoms.

About Mild Cognitive Impairment

Mild cognitive impairment (MCI) is a syndrome defined as an intermediate stage between the expected cognitive decline of normal aging and the more pronounced decline of dementia. It involves problems with memory, language, thinking and judgment that are greater than typical age-related changes. Although MCI can present with a variety of symptoms, when memory loss is the predominant symptom it is termed “amnestic MCI” and is frequently seen as a prodromal stage of Alzheimer’s disease. Prevalence in population-based epidemiological studies ranges from 3% to 19% in adults older than 65 years. There is no proven treatment or therapy for MCI.

About Avraham Pharmaceutical

Founded in 2010, Avraham Pharmaceuticals has raised more than $12 million to advance the development of its unique, multi-functional drug substance, ladostigil, currently undergoing two Phase 2 clinical trials for the treatment of Alzheimer’s disease and mild cognitive impairment. The Company has been capitalized by Clal Biotechnology Industries Ltd., the Pontifax Fund and Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University.

References

Weinstock M, Bejar C, Wang RH, et al. (2000). “TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer’s disease”. Journal of Neural Transmission. Supplementum (60): 157–69.PMID 11205137.
Weinreb O, Mandel S, Bar-Am O, et al. (January 2009). “Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer’s disease drugs”. Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics 6 (1): 163–74.doi:10.1016/j.nurt.2008.10.030. PMID 19110207.
Weinstock M, Luques L, Bejar C, Shoham S (2006). “Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression”. Journal of Neural Transmission. Supplementum (70): 443–6. PMID 17017566.
Weinreb O, Amit T, Bar-Am O, Youdim MB (December 2007). “Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy”. Annals of the New York Academy of Sciences 1122: 155–68.doi:10.1196/annals.1403.011. PMID 18077571.
Weinstock M, Poltyrev T, Bejar C, Youdim MB (March 2002). “Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression”.Psychopharmacology 160 (3): 318–24. doi:10.1007/s00213-001-0978-x. PMID 11889501.
Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim M (June 2003). “A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson’s disease”. Progress in Neuro-psychopharmacology & Biological Psychiatry 27 (4): 555–61. doi:10.1016/S0278-5846(03)00053-8.PMID 12787840.

Contact Us

Yona Geffen CEO
Avraham Pharmaceuticals Ltd.
42 Hayarkon st.
Northern Industrial Zone
Yavneh, 81227
Israel

WO1998027055A1 *	18 Dec 1997	25 Jun 1998	Teva Pharmaceutical Industries, Ltd.	Aminoindan derivatives
WO2005051371A1	28 Sep 2004	9 Jun 2005	Technion Research & Development Foundation Ltd.	Compositions and methods for treatment of cardiovascular disorders and diseases
WO2006130726A2	31 May 2006	7 Dec 2006	Teva Pharmaceutical Industries, Ltd.	Use of ladostigil for the treatment of multiple sclerosis
WO2007087029A2 *	11 Dec 2006	2 Aug 2007	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Use of low-dose ladostigil for neuroprotection
WO2009022345A1	14 Aug 2008	19 Feb 2009	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Phenyl carbamates for the treatment of multiple sclerosis
WO2009022346A2	14 Aug 2008	19 Feb 2009	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Phenyl carbamates for treating gastrointestinal inflammation
WO2012059920A1	2 Nov 2011	10 May 2012	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Ladostigil dosage regime
US6251938	18 Jun 1999	26 Jun 2001	Teva Pharmaceutical Industries, Ltd.,	Phenylethylamine derivatives
US6303650	18 Jun 1999	16 Oct 2001	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Aminoindan derivatives
US6538025	31 Aug 2001	25 Mar 2003	Teva Pharmaceutical Industries, Ltd.	Aminoindan derivatives
US7335685	22 Feb 2006	26 Feb 2008	Teva Pharmaceutical Industries, Ltd.	Crystals of ladostigil tartrate, methods of production and pharmaceutical compositions thereof
US7375249	21 Feb 2006	20 May 2008	Teva Pharmaceutical Industries Ltd.	Process for the synthesis of enantiomeric indanylamine derivatives
US7476757	15 Apr 2008	13 Jan 2009	Teva Pharmaceutical Industries Ltd.	Process for the synthesis of enantiomeric indanylamine derivatives
US7491847	15 Nov 2006	17 Feb 2009	Teva Pharmaceutical Industries, Ltd.	Methods for isolating propargylated aminoindans
US20050222123	27 Jan 2005	6 Oct 2005	North Shore-Long Island Jewish Research Institute	Cholinesterase inhibitors for treating inflammation
US20060189685	24 Feb 2006	24 Aug 2006	Daniella Licht	Formulations of ladostigil tartrate
US20060189819	22 Feb 2006	24 Aug 2006	Teva Pharmaceutical Industries, Ltd.	Crystals of ladostigil tartrate, methods of production and pharmaceutical compositions thereof
US20060199974	21 Feb 2006	7 Sep 2006	Teva Pharmaceutical Industries Ltd.	Process for the synthesis of enantiomeric indanylamine derivatives
US20070088082	28 Sep 2006	19 Apr 2007	Judith Aronhime	Polymorphic forms of ladostigil tartrate
US20070093549	28 Sep 2006	26 Apr 2007	Judith Aronhime	Methods for preparation of ladostigil tartrate crystalline form A1
US20070112217	15 Nov 2006	17 May 2007	Anton Frenkel	Methods for isolating propargylated aminoindans
US20070135518	8 Dec 2006	14 Jun 2007	Marta Weinstock-Rosin	Use of low-dose ladostigil for neuroprotection
US20070203232	23 Feb 2007	30 Aug 2007	Victor Piryatinsky	Propargylated aminoindans, processes for preparation, and uses thereof
US20070232691	28 Mar 2007	4 Oct 2007	Tamar Goren	Use of ladostigil for the treatment of schizophrenia
US20070293583	11 Dec 2006	20 Dec 2007	Marta Weinstock-Rosin	Use of low-dose ladostigil for neuroprotection

US5532415 *	Mar 28, 1995	Jul 2, 1996	Teva Pharmaceutical Industries Ltd.	R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof
US5703059 *	Jan 19, 1994	Dec 30, 1997	British Biotech Pharmaceuticals Ltd.	Disaccharide ligands for selectins
US5936000 *	Jan 16, 1996	Aug 10, 1999	Pharmacia & Upjohn Company	2-aminoindans as selective dopamine D3 ligands
US6271261 *	Jun 24, 1997	Aug 7, 2001	Smithkline Beecham Corporation	IL-8 receptor antagonists
US6271263 *	Mar 2, 1999	Aug 7, 2001	Teva Pharmaceutical Industries, Ltd.	Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US6303650 *	Jun 18, 1999	Oct 16, 2001	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Aminoindan derivatives
US6462222 *	Aug 31, 2001	Oct 8, 2002	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Aminoindan derivatives
US6538025 *	Aug 31, 2001	Mar 25, 2003	Teva Pharmaceutical Industries, Ltd.	Aminoindan derivatives
US6737547 *	Sep 15, 1999	May 18, 2004	Teva Pharmaceutical Industries, Ltd.	Compositions containing and methods of using N-acyl-1H-aminoindenes
US20040010038 *	Feb 27, 2003	Jan 15, 2004	Eran Blaugrund	Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors

Citing Patent	Filing date	Publication date	Applicant	Title
US7649115	Jun 1, 2006	Jan 19, 2010	Jenrin Discovery, Inc.	MAO-B inhibitors useful for treating obesity
US8541475	Dec 31, 2009	Sep 24, 2013	Jenrin Discovery, Inc.	MAO-B inhibitors useful for treating obesity
US8569545	Jun 2, 2009	Oct 29, 2013	Generics (Uk) Limited	Process for the preparation of enantiomerically pure amines
US8809589	Jul 18, 2013	Aug 19, 2014	Generics [Uk] Limited	Process for the preparation of enantiomerically pure amines
US20070088004 *	Jun 1, 2006	Apr 19, 2007	Mcelroy John F	MAO-B inhibitors useful for treating obesity
US20100168068 *	Dec 31, 2009	Jul 1, 2010	Jenrin Discovery	Mao-b inhibitors useful for treating obesity
US20110184071 *	Jun 2, 2009	Jul 28, 2011	Vinayak Gore	process for the preparation of amines
US20110218360 *		Sep 8, 2011	Dr. Reddy’s Laboratories Ltd.	Preparation of rasagiline and salts thereof
CN103443111A *	Apr 2, 2012	Dec 11, 2013	高砂香料工业株式会社	Novel ruthenium complex and process for producing optically active alcohol compound using same as catalyst
CN103443111B *	Apr 2, 2012	Mar 2, 2016	高砂香料工业株式会社	钌配合物以及以该配合物作为催化剂的光学活性醇化合物的制备方法
WO2013118126A1	Feb 11, 2013	Aug 15, 2013	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Ladostigil therapy for immunomodulation

Ladostigil
Systematic (IUPAC) name

[(3R)-3-(prop-2-ynylamino)indan-5-yl]-N-propylcarbamate
Clinical data
Routes of administration	Oral
Legal status
Legal status	Uncontrolled
Identifiers
CAS Number	209349-27-4
ATC code	none
PubChem	CID 208907
ChemSpider	181005
UNII	SW3H1USR4Q
Synonyms	[N-propargyl-(3R)-aminoindan-5yl]-N-propylcarbamate
Chemical data
Formula	C₁₆H₂₀N₂O₂
Molar mass	272.34 g/mol